Hubs of Liver and Pancreatic Cancer

Hubs of Liver and Pancreatic Cancer

Liver and pancreatic cancer share several standard hubs. This article discusses YKL-40, IL-6, hepatic resection, and treatment options for each. It also explains the underlying pathophysiology of the disease and the role of immunotherapy. Please see our other articles on pancreatic and liver cancer for more information. Moreover, check out our related articles on IL-6, IL-10, and IL-6.


In previous studies, serum levels of YKL-40 have been linked to the presence of the pancreatic cancer genes APC and NRAS. This finding may be relevant to a broader population of cancer patients. However, the exact relationship between YKL-40 and liver or pancreatic cancer has not yet been confirmed. In addition to being secreted by macrophages, YKL-40 may also modulate angiogenesis during tissue repair.


The current study investigated the relationship between IL-6 and ACP. They found that IL-6 contributes to the activation of PSCs and Col1 production in pancreas samples from ACP patients. These findings suggest that IL-6 regulates TGF-b1/Smad signalling in the pancreas. This finding raises the possibility of a possible link between IL-6 and pancreatic cancer.

Standard hubs of liver and pancreatic cancer

We previously reported a relationship between liver and pancreatic cancer, with nine out of every ten hub nodes being shared. In this study, we have isolated 18 hubs and compared their activation actions. We found that GAPDH, MYC, and EGFR are standard pancreatic and liver cancer hubs. These proteins were highly expressed in pancreatic and liver cancer tissues and negatively correlated with patient survival.

Hepatic resection

The results of the present study indicate that hepatic resection is an effective treatment for patients with metastatic disease. The overall survival rates were comparable between patients with metastatic liver cancer and those without such conditions. The extent of resection depended on the location and size of metastatic lesions within the liver. The study also examined the surgical technique used for liver resection.

Genetic risk screening

You may consider genetic testing if you are concerned about your risk of developing either cancer. Genetic testing can help identify specific mutations in your genes that contribute to the development of your cancer. Your healthcare provider or genetic counsellor may recommend germline or somatic testing. Genetic risk testing for liver and pancreatic cancer can help determine if you are at high risk of developing cancer. Your health care provider can discuss the dangers of gene risk screening for pancreatic and liver cancer with you.

Pain in the abdomen or back

Many patients were suffering from pancreatic cancer experience pain in the back and abdomen. Because the tumours are pressing on the celiac plexus, they may feel bloated. The pain can be so severe that it can lead to bowel obstruction. The good news is that pancreatic cancer is treatable, and new therapies are being studied to alleviate patients' pain. However, pain in the back and abdomen can often be misdiagnosed as something else.


There are different treatment options for patients with this type of cancer. Surgical removal of the tumour is one option. But surgery may not be an option for some patients. Luckily, new technology has made it easier to perform minimally invasive procedures. One of these is the Yttrium-90 (Y-90) procedure. In this procedure, Y-90 is implanted onto a tiny glass or resin particle and guided through an artery to the liver or pancreatic tumour. After this, thin wires at the tip of the needle are opened up and inserted into the tumour. The radiation from these microspheres will eventually destroy the cancer cells in the affected areas, leading to a better quality of life.